Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: How Do Anti‐HLA Antibodies Impact?
Clinical Transplantation · 2024
DOI: 10.1111/ctr.70035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Gizem Zengin Ersoy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Medical Park Bahçelievler Hospital, Department of Pediatric Hematology Oncology & Pediatric Bone Marrow Transplantation Unit, Al…. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, beta-Thalassemia, Graft vs Host Disease, HLA Antigens. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Aim
To investigate the effects of anti‐human Leucocyte Antigen (HLA) antibody positivity on early hematopoietic stem cell transplantation (HSCT) results in patients with thalassemia major (TM).
Methods
One hundred and twenty‐four HLA‐matched HSCTs were performed in patients with TM between 2015 and 2022. Ninety‐one patients were screened for anti‐HLA antibodies by testing panel reactive antigens (PRA). Demographic and transplantation characteristics of patients were recorded. The presence of PRA was tested with the Antibody Testing Assay (Luminex LIFECODES HLA Antibody Identification System).
Results
The number of PRA‐positive patients was 54. There was no relationship between acute graft versus host disease (GVHD), chronic GVHD, grade of GVHD, and viral reactivation of the patients. However, platelet engraftment took around 3 days longer in the PRA‐positive group ( p = 0.05). The median number of erythrocyte transfusions was significantly higher in PRA‐positive patients in the post‐transplant period ( p = 0.003), as was the median number of platelet transfusions ( p = 0.003). Treosulfan conditioning increased the stable mixed chimerism (MC) rate by 3.8‐fold ( p = 0.011). In contrast, reduced rates of MC were found in patients who received matched unrelated donor cells or peripherally derived stem cells ( p = 0.011 and p = 0.039, respectively) in the posttransplantation period in TM patients. PRA‐positivity did not affect MC ( p = 0.478). However, 80% of patients who had primary graft failure ( n = 5; p = 0.59) and 75% of patients who died ( n = 4) were PRA positive ( p = 0.64), but these results were statistically insignificant due to the low number of patients.
Conclusion
Anti‐HLA antibodies primarily delayed platelet engraftment in TM patients and increased the erythrocyte and thrombocyte transfusion requirements. Although PRA positivity was more common in patients with primary graft failure or who died, there was no statistically significant impact of PRA positivity on chimerism, acute or chronic GVHD, viral activation, or mortality rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Medical Park Bahçelievler Hospital, Department of Pediatric Hematology Oncology & Pediatric Bone Marrow Transplantation Unit, Altınbaş University, Istanbul, Turkey.
- Faculty of Medicine, Medical Park Bahçelievler Hospital, Department of Pediatric Hematology Oncology & Pediatric Bone Marrow Transplantation Unit, Istinye University, Istanbul, Turkey.
- Istinye University, Department of Immunology, Laboratory of Immunology and HLA Analysis, Istanbul, Turkey.
- Umraniye Research & Training Hospital, Department of Pediatric Hematology & Oncology, Medical Sciences University, Istanbul, Turkey.
- Aydin University Pediatric Hematology & Oncology, Istanbul, Turkey.
ORCID-Profile: Gizem Zengin Ersoy, Basak Adakli Aksoy
Zitieren
APA
Ersoy, G. Z., Aksoy, B. A., Erdem, M., Karataş, L., Aydoğdu, S., Öner, Ö. B., Dikme, G., Bozkurt, C., & Fışgın, T. (2024). Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: How Do Anti‐HLA Antibodies Impact?. Clinical Transplantation. https://doi.org/10.1111/ctr.70035
Vancouver
Ersoy GZ, Aksoy BA, Erdem M, Karataş L, Aydoğdu S, Öner ÖB, et al. Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: How Do Anti‐HLA Antibodies Impact?. Clinical Transplantation. 2024. doi:10.1111/ctr.70035
BibTeX
@article{Ersoy2024,
author = {Ersoy, Gizem Zengin and Aksoy, Basak Adakli and Erdem, Melek and Karataş, Lokman and Aydoğdu, Selime and Öner, Özlem Başoğlu and Dikme, Gürcan and Bozkurt, Ceyhun and Fışgın, Tunç},
title = {Outcomes of Hematopoietic Stem Cell Transplantation in Patients With Thalassemia Major: How Do Anti‐HLA Antibodies Impact?},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.70035}
}
EUVIMED